Evidence-based medicine and the need for non-commercial clinical research directed towards therapeutic innovation

Experimental Biology and Medicine

Volumn 227, Issue 7, 2002, Pages 435-437

  Horrobin, David F ^a  

^a Laxdale Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; NEUROLEPTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; CARDIOVASCULAR DISEASE; CASE REPORT; CLINICAL RESEARCH; DRUG EFFICACY; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; MALE; METABOLIC DISORDER; NOTE; SCHIZOPHRENIA;

EID: 0036656438     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020222700706     Document Type: Note

References (7)

1. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 158:1449-1454, 2001.
2. Horrobin DF. The philosophical basis of peer review and the suppression of innovation. J Am Med Assoc 263:1438-1441, 1990.
3. Wurtman RJ, Bettiker RL. The slowing of treatment discovery, 1965-1995. Nat Med 1: 1122-1125, 1995.
4. Oldham JM. Heinz E. Lehmann, MD (1911-2000): Obituary. Arch Gen Psychiatry 58:1178, 2001.
5. Horrobin DF. Realism in drug discovery: could Cassandra be right? Nat Biotechnol 19:1099-1100, 2001.
6. Horrobin DF. Innovation in the pharmaceutical industry. J R Soc Med 93:341-345, 2000.
7. Rosenberg L. Physician-scientists: endangered and essential. Science 283:331-332, 1999.